학술논문
Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children
Document Type
article
Author
Elena Chiappini; Catiuscia Lisi; Vania Giacomet; Paola Erba; Stefania Bernardi; Paola Zangari; Antonio Di Biagio; Lucia Taramasso; Carlo Giaquinto; Osvalda Rampon; Clara Gabiano; Silvia Garazzino; Claudia Tagliabue; Susanna Esposito; Eugenia Bruzzese; Raffaele Badolato; Domenico Zanaboni; Monica Cellini; Maurizio Dedoni; Antonio Mazza; Andrea Pession; Anna Maria Giannini; Filippo Salvini; Icilio Dodi; Ines Carloni; Salvatore Cazzato; Pier Angelo Tovo; Maurizio de Martino; Luisa Galli; for the Italian Register for HIV Infection in Children
Source
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-11 (2022)
Subject
Language
English
ISSN
1471-2334
Abstract
Abstract Background Early start of highly active antiretroviral therapy (HAART) in perinatally HIV-1 infected children is the optimal strategy to prevent immunological and clinical deterioration. To date, according to EMA, only 35% of antiretroviral drugs are licenced in children 25%. At last check, during the off label regimen, the 80% (40/50) of patients had an undetectable VL, and 90% (45/50) of them displayed CD4 + T lymphocyte percentage > 25%. The most widely used off-label drugs were: dolutegravir/abacavir/lamivudine (16%; 8/50), emtricitbine/tenofovir disoproxil (22%; 11/50), lopinavir/ritonavir (20%; 10/50) and elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide (10%; 10/50). At logistic regression analysis, detectable VL before starting the current HAART regimen was a risk factor for receiving an off-label therapy (OR: 2.41; 95% CI 1.13–5.19; p = 0.024). Moreover, children